Return |
Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79.
What are the vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs)?
NSAIDs reduce pain, fever, and inflammation. Traditional NSAIDs include aspirin, ibuprofen, and naproxen.
Selective COX-2 inhibitors (coxibs) are a newer type of NSAID that target the COX-2 inflammatory protein.
The long-term use of NSAIDs is limited by serious gastrointestinal (GI) side effects.
This summary is based on a meta-analysis of 754 randomized controlled trials that included 353,809 people. 280 trials (124,513 people) compared NSAIDs with placebo, and 474 trials (229,296 people) compared 2 different NSAIDs. The publication period was 1990 to 2011.
In studies providing individual participant data, the average age at start of treatment was 61 years.
NSAIDs included were coxibs, diclofenac, ibuprofen, and naproxen.
Outcomes included major vascular events (non-fatal heart attack, non-fatal stroke, or vascular death); major coronary events (non-fatal heart attack or heart problems); heart failure; and gastrointestinal complications (perforation, obstruction, or bleed).
As shown in the Table below, compared with placebo,
Non-steroidal anti-inflammatory drugs (NSAIDs), except for naproxen, increase major coronary events.
All NSAIDs increase heart failure and upper gastrointestinal complications more than placebo. The absolute increase in risk is small, but the complications can be serious.
Relative increase with NSAIDs compared with placebo or no treatment
NSAIDs | Vascular events | Coronary events | Heart failure | Vascular death | GI complications |
---|---|---|---|---|---|
Coxibs | 37% increase | 76% increase | 128% increase | 58% increase | 81% increase |
Diclofenac | 41% increase | 70% increase | 85% increase | 65% increase | 89% increase |
Ibuprofen | No increase | 122% increase | 149% increase | No increase | 97% increase |
Naproxen | No increase | No increase | 87% increase | No increase | 322% increase |
This Evidence Summary was originally prepared for the McMaster Optimal Aging Portal.
Published: Monday, August 14, 2017
Please note that the information contained herein is not to be interpreted as an alternative to medical advice from a professional healthcare provider. If you have any questions about any medical matter, you should consult your professional healthcare providers, and should never delay seeking medical advice, disregard medical advice or discontinue medication based on information provided here.
This Evidence Summary was printed from the PAIN+ CPN website on 2024/11/21. To view other Evidence Summaries or to register to receive email notifications about new Evidence Summaries, please visit us at https://www.painpluscpn.ca/Articles/EvidenceSummaries |